Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets
You may also be interested in...
Glaxo Seeks Indian Consumer Growth, Expanded Capacity
GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”
Glaxo Seeks Indian Consumer Growth, Expanded Capacity
GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”
GSK Shoots For Next Growth Phase In India With Bigger Push Into Vaccines, Pharma And Consumer Health
For the first time, the global board of directors of the British pharma and consumer healthcare giant met in India, and a series of moves to power further growth could be on the way.